We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Endo’s stock price hasn’t at all recovered from a sharp decline thanks to generics price erosion and a gloomy outlook for the company’s business. But CEO Paul Campanelli snagged a huge pay pump in 2018 anyway—and not just because the board thinks he's don